Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB on Treating Vitiligo

NCT03608917 | Completed DMC

• 1 other identifier: XijingH-PF-20180116
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.Total Glucosides of Paeony(TGP) As a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）. Paeoniflorin accounted for more than 90% of the TGP, is the main active ingredient of white peony root.By pharmacological and clinical studies of TGP, it have found that the mechanism of TGP is unique and mainly acts on the upstream of the immune response - inhibiting the presentation of antigens. It is different from immunosuppressive agents on T, B lymphocytes, or hormones and other drugs acting on the whole process.
2. 2.Vitiligo Vitiligo is a pigment deprived skin disease caused by the destruction of melanocytes, the global incidence of about 1%. The pathogenesis is not yet clear, the current study shows that oxidative stress and autoimmunity is an important part of its occurrence and development.
3. 3.The basic and clinical research of TGP used in vitiligo The ratio of cluster of differentiation 4+ / cluster designation 8+ T cell vs. cluster of differentiation 4+ chronotropic dose 25+ in the peripheral blood of patients with vitiligo could be significantly increase, after patients treatment by TGP combined with tacrolimus. Thereby enhancing the patient's maintenance of immune self-stability and Immune tolerance ability, promoting the healing of skin lesions. It showed significant effect in stable vitiligo,when patients treated by autologous epidermal grafting combined with TGP.

Conditions

Vitiligo

Keywords

Vitiligo; Total Glucosides of Paeony(TGP); narrow-band ultraviolet B (NB-UVB)

Outcome Measures

Primary Outcomes (1)

• Vitiligo Area and Severity Index (VASI)

  The extent of residual depigmentation is expressed by the following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. The VASI for each body part is the product of the palm unit and the degree of depigmentation of the unit.VASI=Σall body sites (hand units) × depigmentation

  Change from Baseline VASI at 24 weeks

Secondary Outcomes (1)

• The number of recovered vitiligo area

  8 weeks

Study Arms (2)

Treatment group

EXPERIMENTAL

Drug:Total Glucosides of Paeony (TGP) 1. Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day) 2. Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally.

Drug: Total Glucosides of Paeony(TGP); Device: Narrow band-ultraviolet b（NB-UVB）

Control group

PLACEBO COMPARATOR

Drug:Total Glucosides of Paeony (TGP) analogue 1. Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day) 2. Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally.

Device: Narrow band-ultraviolet b（NB-UVB）; Drug: Total Glucosides of Paeony(TGP) analogue

Interventions

Total Glucosides of Paeony(TGP) DRUG

Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）

Treatment group

Narrow band-ultraviolet b（NB-UVB） DEVICE

phototherapy on treating vitiligo

Control group; Treatment group

Total Glucosides of Paeony(TGP) analogue DRUG

Total Glucosides of Paeony(TGP) analogue as a placebo for Control group

Control group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• subjects must be clinically diagnosed by the investigator to have sporadic Vitiligo in proceeding
• Vitiligo with at least 3 depigmented areas in different anatomy areas including：1%\~50% of the total body surface area (BSA) in （face /trunk/limbs）,the minimum area is greater than 1 cm2 .Males or females, 18 Years to 65 Years of age at the time of signing the informed consent document.
• Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.

You may not qualify if:

• Actively spreading vitiligo,or stable vitiligo;
• Subjects with segmental, acromegaly, mucous, generalized, mixed and undetermined vitiligo.;
• Secondary vitiligo subjects with history of UV photosensitivity
• Subjects with other diseases unsuitable for ultraviolet light therapy and TGP ; .Use of vitiligo topical drugs within 2 weeks or, system treatment and phototherapy for the treatment of vitiligo within four weeks.
• History of allergy to any component of the total glucosides of paeony(TGP);
• Subjects with a history of chronic diarrhea or peptic ulcer within 1 year .Women who are pregnant or breast feeding,or preparing for pregnancy. .Subjects with serious medical diseases or history of mental system abnormal. .Use of any prior and concomitant therapy not listed above that may interfere with the objective of the study as per discretion of the investigator.

Sponsors & Collaborators

• xjpfW: lead
• Air Force General Hospital of the PLA: collaborator
• First Hospital of China Medical University: collaborator
• Chinese Academy of Medical Sciences: collaborator

Study Sites (1)

Xijing Hospital

Xi'an, Shaanxi, 710032, China

Location

MeSH Terms

Conditions

Vitiligo

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Tianwen Gao, Prof

  Dermatology Derpartment of Xijing Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Dermatology

Study Record Dates

• First Submitted: July 4, 2018
• First Posted: August 1, 2018
• Study Start: April 17, 2018
• Primary Completion: April 30, 2019
• Study Completion: July 31, 2019
• Last Updated: March 11, 2021

Record last verified: 2021-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)